AR066587A1 - Forma de dosificacion que comprende 10 - [( 3s))-1-azabiciclo[2.2.2]oct-3 -ilmetil]-10h-fenotiazina provista en forma adecuada para la administracion oral de una dosis diaria de 1 mg a 3 mg - Google Patents
Forma de dosificacion que comprende 10 - [( 3s))-1-azabiciclo[2.2.2]oct-3 -ilmetil]-10h-fenotiazina provista en forma adecuada para la administracion oral de una dosis diaria de 1 mg a 3 mgInfo
- Publication number
- AR066587A1 AR066587A1 ARP080102067A ARP080102067A AR066587A1 AR 066587 A1 AR066587 A1 AR 066587A1 AR P080102067 A ARP080102067 A AR P080102067A AR P080102067 A ARP080102067 A AR P080102067A AR 066587 A1 AR066587 A1 AR 066587A1
- Authority
- AR
- Argentina
- Prior art keywords
- oct
- oral administration
- daily dose
- dosage form
- azabiciclo
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- HOKDBMAJZXIPGC-INIZCTEOSA-N 10-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C[C@H]1C(CC2)CCN2C1 HOKDBMAJZXIPGC-INIZCTEOSA-N 0.000 abstract 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 abstract 1
- 108010003541 Platelet Activating Factor Proteins 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002617 leukotrienes Chemical class 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forma de dosificacion que comprende 10-[(3S)-1-azabiciclo[2.2.2]oct-3-ilmetil]-10H-fenotiazina, provista en forma adecuada para la administracion oral de una dosis diaria de 1 mg a 3 mg. Reivindicacion 8: El uso de 10-[(3S)-1-azabiciclo[2.2.2]oct-3-ilmetil]-10H-fenotiazina, o por lo menos una sal farmacéuticamente aceptable para uso farmacéutico de la misma, en la preparacion de un fármaco que se presenta en una forma de dosificacion adecuada para la administracion oral de una dosis diariade 1 mg a 3 mg para la prevencion y/o tratamiento de trastornos alérgicos, muy especialmente la rinitis alérgica. Reivindicacion 14: El uso de acuerdo con cualquiera de las reivindicaciones 8 a 13, que se caracteriza por el hecho de que dichofármaco se utiliza en combinacion con otro ingrediente activo seleccionado entre antihistamínicos, inhibidores de la lipoxigenasa, antiinflamatorios, inhibidores de la liberacion de citoquinas proinflamatorias, antagonistas del receptor deleucotrienos, o compuestos que controlar la liberacion de mediadores de los mastocitos, como por ejemplo leucotrienos, prostaglandinas, tromboxano A2 o factor activador del de plaquetas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0755075A FR2916142A1 (fr) | 2007-05-15 | 2007-05-15 | Forme pharmaceutique comprenant du (10-[(3s)-1-azabicyclo [2.2.2]oct-3-ylmethyl]-10h-phenothiazine se presentant sous une forme appropriee pour l'administration d'unde dose journaliere comprise entre 1 et 3 mg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066587A1 true AR066587A1 (es) | 2009-09-02 |
Family
ID=38752476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102067A AR066587A1 (es) | 2007-05-15 | 2008-05-15 | Forma de dosificacion que comprende 10 - [( 3s))-1-azabiciclo[2.2.2]oct-3 -ilmetil]-10h-fenotiazina provista en forma adecuada para la administracion oral de una dosis diaria de 1 mg a 3 mg |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR066587A1 (es) |
| FR (1) | FR2916142A1 (es) |
| TW (1) | TW200906417A (es) |
| WO (1) | WO2008138968A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021503499A (ja) * | 2017-11-17 | 2021-02-12 | ニューラナ ファーマスーティカルズ, インコーポレイテッドNeurana Pharmaceuticals, Inc. | トルペリゾンを投与する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2522660A1 (fr) * | 1982-03-05 | 1983-09-09 | Pharmuka Lab | Isomere levogyre de la mequitazine, son procede de preparation et medicaments le contenant |
| JPH07188040A (ja) * | 1993-12-27 | 1995-07-25 | Taisho Pharmaceut Co Ltd | 鼻炎治療用組成物 |
| FR2772029B1 (fr) * | 1997-12-08 | 2000-02-25 | Pf Medicament | Procede de preparation de la mequitazine et nouvel intermediaire de synthese |
| JP2000191536A (ja) * | 1998-10-20 | 2000-07-11 | Taisho Pharmaceut Co Ltd | メキタジン配合内服固形製剤 |
| WO2005037245A2 (en) * | 2003-10-21 | 2005-04-28 | Direct-Haler A/S | A multiple route medication for the treatment of rhinitis and asthma |
| JP2006096749A (ja) * | 2004-08-31 | 2006-04-13 | Takeda Chem Ind Ltd | 感冒用医薬組成物 |
| FR2896690B1 (fr) * | 2006-01-30 | 2008-05-02 | Pierre Fabre Medicament Sa | Utilisation de l'enantiomere(s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique |
-
2007
- 2007-05-15 FR FR0755075A patent/FR2916142A1/fr not_active Withdrawn
-
2008
- 2008-05-13 TW TW097117537A patent/TW200906417A/zh unknown
- 2008-05-15 AR ARP080102067A patent/AR066587A1/es unknown
- 2008-05-15 WO PCT/EP2008/055971 patent/WO2008138968A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008138968A3 (en) | 2009-05-22 |
| WO2008138968A2 (en) | 2008-11-20 |
| TW200906417A (en) | 2009-02-16 |
| WO2008138968A4 (en) | 2009-07-02 |
| FR2916142A1 (fr) | 2008-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR048705A1 (es) | Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| AR061771A1 (es) | Sistema de administracion terapeutica | |
| ECSP055733A (es) | Tabletas dispersables de deferacirox | |
| AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
| GT200100211AA (es) | Compuestros de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos. (patentefraccionaria no. 1 de la solicitud de patente de invencion no. pi-2001-0211. | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
| CR9662A (es) | Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| JP2010222367A5 (es) | ||
| AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
| PE20250018A1 (es) | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida | |
| ECSP044986A (es) | Composicion farmaceutica que comprende lumiracoxib | |
| AR068820A1 (es) | Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica y uso | |
| PE20040973A1 (es) | Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroidales | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| AR028525A1 (es) | Sistema terapeutico transdermal para la administracion de lerisetron | |
| AR046146A1 (es) | Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
| AR066587A1 (es) | Forma de dosificacion que comprende 10 - [( 3s))-1-azabiciclo[2.2.2]oct-3 -ilmetil]-10h-fenotiazina provista en forma adecuada para la administracion oral de una dosis diaria de 1 mg a 3 mg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |